Lung Cancer

We recommend

Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene

24. 5. 2023 Source: Lung Cancer

Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with the G12C mutation of the KRAS oncogene. The newly published study presented below investigated its intracranial activity.

Pokroky v léčbě pokročilého NSCLC s mutací G12C onkogenu KRAS

Na mutace onkogenu KRAS, včetně nejběžnější varianty G12C, se dlouho nedařilo cílit léčbu. Nedávný…

19. 6. 2023 Source: Lung Cancer

Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy –⁠ Case Study

Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC)…

19. 6. 2023 Source: Lung Cancer

Articles on this topic

Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS –⁠ a case study

We present a case study of an elderly patient with non-small cell lung cancer (NSCLC) treated…

30. 10. 2024 Source: Lung Cancer

Inhibition of Mutated KRAS Protein as a New Option for Targeted Treatment of Non-Small Cell Lung Cancer

RAS proteins are molecular switches for several intracellular signaling pathways. Their…

9. 11. 2023 Source: Lung Cancer

Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene

Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the…

10. 10. 2023 Source: Lung Cancer

Sotorasib in the Treatment of a Patient with NSCLC and DIC –⁠ A Case Report

Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation.…

24. 5. 2023 Source: Lung Cancer

zdravotní sestra sestřička nemocnice medicína žena

Can We Reach Brain Metastases of Lung Cancer with Anti-EGFR Targeted Therapy?

Information on the penetration of epidermal growth factor receptor tyrosine kinase inhibitors…

11. 1. 2021 Source: Lung Cancer

nemocnice medicína výzkum kancelář studie ordinace

Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe

In June 2020, the journal Radiology and Oncology published the results of an analysis of data…

6. 1. 2021 Source: Lung Cancer

žena lékařka doktorka konzultace špatné zprávy

Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy –⁠ Case Study

We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven…

16. 6. 2020 Source: Lung Cancer

Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation –⁠ Case Study

Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization…

10. 6. 2020 Source: Lung Cancer

How to Communicate and Receive an Oncological Diagnosis

Communicating the truth about a patient's health condition does not have a very long tradition...

4. 6. 2020 Source: Lung Cancer

medicína_konzultace_lékař_pacient_prohlídka_karta

Patient Evaluation of Durvalumab Treatment Results

The interim analysis results of the PACIFIC study, which monitored the efficacy of durvalumab…

31. 3. 2020 Source: Lung Cancer